<DOC>
	<DOCNO>NCT01262586</DOCNO>
	<brief_summary>This study use Continuous Glucose Monitoring ass difference glycemic profile vildagliptin glimepiride .</brief_summary>
	<brief_title>Vildagliptin Glycemic Profiles Assessment Using Continuous Glucose Monitoring Device .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>Type 2 diabetes patient stable metformin 1870 year old Willing perform least 4 capillary blood glucose test per day Type 2 diabetes patient antidiabetic treatment Patients list trial Patients significant diabetic organ disease complication . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Type II Diabetes Mellitus</keyword>
	<keyword>Vildagliptin</keyword>
	<keyword>Glimepiride</keyword>
	<keyword>Continuous glucose monitoring</keyword>
</DOC>